• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolines
• Pharmaceutical and Biochemical Products Medical Target Class

Introduction to Sunitinib malate (CAS No. 341031-54-7) in Modern Pharmaceutical Research

Sunitinib malate, chemically designated as (Z)-N'-[5-[(4,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]pyrimidin-2-yl]-2-(4-methylpiperazin-1-yl)acetamide monomaleate, is a well-known small-molecule inhibitor that has garnered significant attention in the field of oncology and pharmacology. With the CAS number 341031-54-7, this compound is widely recognized for its role in targeted therapy, particularly in the treatment of various cancers. The malate salt form of Sunitinib malate enhances its solubility and bioavailability, making it a highly effective therapeutic agent.

The development of Sunitinib malate represents a milestone in the evolution of anticancer drugs, leveraging advances in structural biology and molecular pharmacology. Its mechanism of action primarily involves the inhibition of multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and others. This multitargeted approach has been instrumental in its clinical success, particularly in the management of renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST).

Recent studies have further elucidated the pharmacokinetic and pharmacodynamic properties of Sunitinib malate, revealing insights into its metabolic pathways and resistance mechanisms. For instance, research published in high-impact journals such as the *Journal of Clinical Oncology* has highlighted the importance of dose adjustments and patient monitoring to mitigate adverse effects associated with prolonged treatment. The compound's ability to cross the blood-brain barrier has also been explored, opening new avenues for its potential use in central nervous system disorders.

The synthesis and characterization of Sunitinib malate (CAS No. 341031-54-7) have been refined through cutting-edge techniques in organic chemistry and crystallography. High-resolution X-ray crystallography has provided detailed structural insights into how Sunitinib malate interacts with its target proteins, enabling medicinal chemists to design more potent derivatives. Additionally, computational modeling techniques such as molecular dynamics simulations have been employed to predict binding affinities and optimize drug-like properties.

In clinical settings, Sunitinib malate has demonstrated remarkable efficacy in phase III trials, leading to its approval by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its approval was based on compelling evidence from randomized controlled trials that showed significant improvements in progression-free survival compared to traditional chemotherapeutic agents. Furthermore, combination therapies involving Sunitinib malate with other targeted agents or immunotherapy have shown promising results in preclinical studies, suggesting potential synergistic effects that could enhance treatment outcomes.

The role of Sunitinib malate extends beyond oncology; emerging research suggests its potential applications in inflammatory diseases and neurodegenerative disorders. For example, studies have indicated that the compound may modulate inflammatory pathways by inhibiting specific kinases involved in cytokine release. This opens up new therapeutic possibilities for conditions such as rheumatoid arthritis or multiple sclerosis, although further investigation is warranted to validate these findings.

From a regulatory perspective, the manufacturing and distribution of Sunitinib malate are subject to stringent quality control measures to ensure consistency and safety. Good Manufacturing Practices (GMP) are rigorously followed by pharmaceutical companies producing this compound, with an emphasis on batch-to-batch reproducibility. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are employed to monitor impurities and ensure compliance with regulatory standards.

The future of Sunitinib malate (CAS No. 341031-54-7) lies in continued innovation and personalized medicine approaches. Advances in genomics and proteomics are enabling researchers to identify biomarkers that can predict response to therapy, allowing for more tailored treatment strategies. Additionally, efforts are underway to develop next-generation inhibitors that build upon the scaffold of Sunitinib malate, aiming to improve efficacy while minimizing side effects.

In conclusion, Sunitinib malate represents a cornerstone in modern oncology therapy, with its multifaceted applications and promising future prospects. The compound's development underscores the importance of interdisciplinary collaboration between chemists, biologists, clinicians, and regulatory experts. As research progresses, it is anticipated that new insights into the mechanisms of action and novel therapeutic applications will continue to emerge, further solidifying the position of Sunitinib malate as a pivotal player in pharmaceutical innovation.

• 215543-92-3(SU 5402)
• 220127-57-1(Imatinib mesylate)
• 231277-92-2(Lapatinib)
• 1204313-51-8(Icotinib Hydrochloride)
• 127653-88-7(Hexanoic acid,6-(5,6-dihydro-7-methyl-5-oxo-11H-pyrido[4,3-c][1]benzazepin-11-ylidene)-)
• 67747-09-5(Prochloraz)
• 388082-78-8(Lapatinib ditosylate monohydrate)
• 184475-35-2(Gefitinib)
• 16568-56-2(21H-Biline-8,12-dipropanoicacid, 2,17-diethyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-)
• 557795-19-4(Sunitinib)